Etonogestrel/ethinyl Estradiol Insert, Extended Release
Product Images NDC 66993-605

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Etonogestrel/ethinyl Estradiol (NDC 66993-605). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Prasco Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Etonogestrel 01)

A horizontal bar chart displaying the number of women with a blood clot out of 10,000 woman-years (WY) across four groups: Non-CHC user, non-pregnant; CHC user; Pregnant; and Postpartum (12 weeks only). Each group shows a range, with postpartum having the highest range (40 to 65) and non-CHC user, non-pregnant the lowest (1 to 5).*

FDA Label Image

Etonogestrel 01a

A forest plot chart showing effect estimates for various studies comparing current versus never use of contraceptives. The x-axis displays effect estimates ranging approximately from -1.5 to 2.0. Individual study results are plotted as points with confidence intervals, with some effect measures labeled such as OR, RR, and HR. The chart includes studies from NICHD Women's Care, French E3N cohort, Shanghai Women's Health, Nurses' Health Study, Oxford Family Planning, and Danish Sex Hormone Register.*

FDA Label Image

Chemical Structure (Etonogestrel 02)

Chemical structure of etonogestrel, an active ingredient in the etonogestrel/ethinyl estradiol vaginal insert.*

FDA Label Image

Chemical Structure (Etonogestrel 03)

Chemical structure of Ethinyl Estradiol, showing the arrangement of carbon rings, hydroxyl groups, and an ethynyl side chain typical of this synthetic estrogen.*

FDA Label Image

Figure 2 (Etonogestrel 04)

A line graph showing the concentration levels of Etonogestrel and Ethinyl Estradiol (EE) in pg/mL over 28 days after vaginal ring insertion. The y-axis on the left represents Etonogestrel concentration and on the right EE concentration. Etonogestrel levels rapidly increase within the first few days and then plateau, while EE levels remain lower and relatively stable throughout the period.*

FDA Label Image

Figure (Etonogestrel 05)

A vertical efficacy chart showing pregnancy rates per 100 women per year associated with various birth control methods. The scale ranges from fewer than 1 to 85 or more pregnancies, categorizing methods from most to least effective: implants, injections, intrauterine devices, sterilization; birth control pills, skin patch, vaginal ring with hormones; condoms and diaphragm; behavioral methods and spermicides; and no birth control.*

FDA Label Image

Figure (Etonogestrel 06)

A bar chart comparing the number of women with a blood clot per 10,000 woman-years among different groups: Non-CHC users/non-pregnant, CHC users, pregnant women, and postpartum women up to 12 weeks. Postpartum women have the highest range (40 to 65), followed by pregnant (5 to 20), CHC users (3 to 12), and non-CHC users/non-pregnant (1 to 5).*

FDA Label Image

Figure A (Etonogestrel 07)

An instructional illustration showing a woman lying on her back with knees bent, intended to demonstrate the positioning for vaginal insertion of the Etonogestrel/Ethinyl Estradiol extended-release insert.*

FDA Label Image

Figure B (Etonogestrel 08)

An instructional illustration depicting a woman squatting and preparing to insert a vaginal extended-release insert, representing the proper positioning for insertion of the Etonogestrel/Ethinyl Estradiol vaginal insert.*

FDA Label Image

Figure C (Etonogestrel 09)

An instructional illustration showing a woman bending one knee and lifting her foot onto a raised surface, likely demonstrating a step in the application or insertion process for a vaginal insert product.*

FDA Label Image

Figure D (Etonogestrel 10)

An instructional line drawing showing a hand holding a circular vaginal insert by its edge. This image illustrates how to hold the Etonogestrel/Ethinyl Estradiol vaginal insert before use.*

FDA Label Image

Figure E (Etonogestrel 11)

An illustration showing a hand holding a small, flexible vaginal insert, likely representing the Etonogestrel/Ethinyl Estradiol vaginal insert for extended release.*

FDA Label Image

Figure F (Etonogestrel 12)

An anatomical illustration showing the female reproductive system with labeled parts including the uterus, vagina, and the placement of the Etonogestrel/Ethinyl Estradiol Vaginal Ring inserted in the vagina.*

FDA Label Image

Figure G (Etonogestrel 13)

An anatomical illustration showing the correct positioning of a vaginal extended-release insert containing etonogestrel and ethinyl estradiol. The diagram demonstrates insertion by a hand into the vaginal canal with the insert placed near the cervix for contraceptive use.*

FDA Label Image

Figure H (Etonogestrel 14)

An anatomical illustration showing a sagittal cross-section of the female pelvic area with a vaginal insert positioned inside. The image depicts the placement of a vaginal extended-release drug delivery system.*

FDA Label Image

Figure I (Etonogestrel 15)

An anatomical illustration showing the placement of a vaginal insert product inside the female reproductive system, highlighting the position of the extended-release etonogestrel and ethinyl estradiol insert labeled under Prasco Laboratories.*

FDA Label Image

Figure J (Etonogestrel 16)

An instructional line drawing showing the insertion of a vaginal extended-release insert. The image depicts a hand placing the insert inside the vaginal canal near the cervix, illustrating proper placement for use of the product containing etonogestrel and ethinyl estradiol.*

FDA Label Image

Principal Display Panel (3 Ring Pouch Box)

Packaging label for Etonogestrel/Ethinyl Estradiol Vaginal Ring, delivering 0.120 mg/0.015 mg per day, an extended release vaginal insert by Prasco Laboratories. The carton includes storage instructions, tamper-evident seal placements, and indicates that the product contains 3 rings and is for Rx only. The label highlights that the product is for vaginal use and includes a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.